ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ImmuneOnco Biopharmaceuticals has announced the successful dosing of the first patient in its Phase III trial of IMM01 (Timdarpacept) combined with azacitidine for treating chronic myelomonocytic leukemia (CMML). This study is notable as it is the first of its kind targeting CD47 for CMML. The company holds global intellectual property rights for IMM01, showcasing its innovative approach in the biopharmaceutical market.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.